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I.  INTRODUCTION 
In recent years, the scientific community has made some 
dramatic advances in the ability to chemically synthesize genome-
length strands of DNA.1  These advances have coincided with a 
growing understanding of the functions of individual genes and gene 
networks.2  With the available knowledge of how whole genomes 
function, and the technical capability of synthesizing whole genomes, 
it will be possible to digitally design novel organisms to perform some 
desired function and then manifest that synthetic organism in the 
real world.3  The J. Craig Venter Institute took the first steps toward 
this goal by creating a synthetic organism controlled entirely by a 
chemically synthesized genome.4  This advance provided: 
a proof of principle for producing cells based on computer-
designed genome sequences.  DNA sequencing of a cellular 
genome allows storage of the genetic instructions for life as 
a digital file . . . . [T]he approach [] developed [by the J. 
Craig Venter Institute] should be applicable to the synthesis 
and transplantation of more novel genomes as genome 
design processes.5 
 Although this ultimate goal of designing novel synthetic 
organisms using synthetic biology sounds like pure science fiction, it 
is entirely possible and would have an enormous impact on 
 
      * J.D., Seton Hall University School of Law, May 2013; Ph.D., University of 
Medicine and Dentistry of New Jersey, 2010; B.S., Rider University, 2002.  Thanks to 
Professor Jordan Paradise for her guidance, Becky Garibotto for her comments and 
encouragement, and Desiree Grace for her thorough editing and assistance. 
 1  See Daniel G. Gibson et al., Creation of a Bacterial Cell Controlled by a Chemically 
Synthesized Genome, 329 SCIENCE 52 (2010). 
 2  Matthias Heinemann & Sven Panke, Synthetic Biology—Putting Engineering Into 
Biology, 22 BIOINFORMATICS 2790, 2790 (2006).  
 3  See Gibson et al., supra note 1, at 55. 
 4  Id. 
 5  Id. at 52. 
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biotechnology and medicine.  In the near future, synthetic organisms 
might be designed to create new sources of food, fuel, and medicine 
that current technology is not capable of producing.  Additionally, 
these benefits will arrive with incredible speed, efficiency, and cost 
effectiveness.6  Designing wholly novel synthetic organisms is still on 
the horizon, however, and presently scientists are left with a 
combination of older methods to innovate in the field of 
biotechnology.  From this older technology, however, the technology 
of synthetic biology has begun to emerge.  In order to make the 
possibilities of synthetic biology a reality in the least amount of time, 
one organization—the BioBricks Foundation—is attempting to 
protect this emerging field from the potentially stifling effects of 
DNA patents by establishing an open-source movement.7  The hope is 
that an open-source synthetic biology commons would encourage 
innovation in ways similar to the wildly successful open-source 
software movement.8  Towards that end, a similar open-source 
approach to synthetic biology might be useful.9  The world of 
synthetic biology, however, poses unique problems to the 
establishment of an open-source community.  These problems 
include incentivizing entities to participate, maintaining openness 
once it is established, and creating useable biomedical products.10 
Part II of this Comment provides an overview of the technology 
of synthetic biology and explains why it is important.  Part III 
introduces the current movement towards open-source synthetic 
biology, as established by the BioBricks Foundation.  Part IV 
describes the past strategies used to establish and maintain other 
analogous open-source biotechnology movements.  Within Part IV, 
three specific strategies are discussed: a copyright approach, a 
contract-based approach, and a patent-based approach to establish 
and maintain a commons.  Part V then assesses whether these 
approaches to maintaining a synthetic biology commons are possible, 
and, if so, what problems might be unique to synthetic biology.  Next, 
Part VI proposes a wholly novel strategy to advance the progress of 
synthetic biology.  This strategy uses an open-source/property-right 
hybrid approach, under the auspices of a standard setting 
 
 6  See generally, Heinemann & Panke, supra note 2. 
 7  About the BioBricks Foundation, BIOBRICKS, http://biobricks.org 
/about-foundation/ (last visited Feb. 11, 2012). 
 8  Id. 
 9  Id. 
 10  See, Andrew W. Torrance, Synthesizing Law For Synthetic Biology, 11 MINN. J.L. 
SCI. & TECH. 629, 650–51 (2010). 
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organization.  Part VII will conclude that a standard setting 
organization for synthetic biology may help to overcome problems 
that cannot be addressed under the three previously described 
strategies. 
II.  SYNTHETIC BIOLOGY: WHAT IS IT AND WHY IS IT? 
A. Recombinant DNA Technology Laid the Foundation for Genetic 
Engineering 
Deoxyribonucleic acid (DNA) is the molecule that encodes the 
instructions for life.11  The DNA language uses four nucleotides—
adenine, thymine, cytosine, and guanine—organized in specific 
sequences to compose the genes responsible for heritable traits.12  
The DNA sequence of an organism gets copied with an extremely 
high fidelity, averaging only one nucleotide error for every billion 
nucleotides copied.13  This DNA sequence is passed on to offspring, 
transmitting genetic information from generation to generation.14 
Scientists have been tinkering with DNA since 1972, when Paul 
Berg, Stanley Cohen, and Hubert Boyer discovered a way to cut and 
paste pieces of DNA together.15  This was followed by many further 
advances in manipulating sequences of DNA, such as the invention of 
the “polymerase chain reaction” (used to amplify pieces of DNA), 
rapid sequencing technology, and targeted gene replacement.16  
Before the development of these technologies, the sheer size and 
chemical-repetitiveness of DNA made it one of the most difficult 
molecules to study and manipulate.17  The advent of the above 
methods, however, has made DNA one of the easiest molecules to 
manipulate.18 
Presently, DNA manipulation techniques have reached a level of 
such sophistication that scientists routinely recombine the DNA 
sequences within a species (or even between species), resulting in 
novel DNA sequences that do not exist in nature.19  Scientists have 
used this recombinant DNA technology (“rDNA technology”) in 
 
 11  BRUCE ALBERTS ET AL., MOLECULAR  BIOLOGY  OF  THE  CELL 193 (4th ed. 2002). 
 12  Id. at 194. 
 13  Id. at 236. 
 14  Id. at 195. 
 15  Id. at 492. 
 16  Id. 
 17  ALBERTS ET AL., supra note 11, at 491. 
 18  Id. 
 19  Id. at 493. 
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numerous applications, impacting various fields including medicine, 
research, and agriculture.20  Despite these advances, however, rDNA 
technology has limited scientists in some ways.21  Generally, rDNA 
techniques involve manipulating a small number of genes with each 
modification involving a time consuming procedure.22  Most scientific 
advances using rDNA technology involves the engineering of a single 
gene because of the time constraints and scientists’ superficial 
understanding of how genes work alongside one another.23  For 
example, recombinant human insulin, which has almost entirely 
replaced insulin derived from animal sources,24 is synthesized by 
expressing a single human insulin gene in the bacteria E. Coli.25  In 
the specific case of human insulin production, manipulation of a 
single gene is sufficient to achieve the desired result: creating an 
alternative source of insulin for people with diabetes.26  In some 
situations, however, manipulating single genes is not sufficient, and 
in those cases the emerging technology of synthetic biology is 
allowing scientists to move beyond the limitations imposed by 
recombinant DNA techniques.27 
 
 20  ALBERTS ET AL., supra note 11, at 491 (rDNA technology has been used in the 
classification of genes/proteins and studying regulatory networks of genes); M.J. 
The, Human Insulin: DNA Technology’s First Drug, 46 AM. J. OF HOSP. PHARMACY 11 
(Nov. 1989) (mass production of human insulin as a replacement for insulin derived 
from animal sources); Roundup Ready System, MONSANTO.COM, 
http://www.monsanto.com /weedmanagement/Pages/roundup-ready-system.aspx 
(last visited Feb. 11, 2012) (genetically modified plants developed using rDNA 
technology increase crop yields).   
 21  See, e.g., Suzanne Cheng, Carita Fockler, Wayne M. Barnes & Russel Higuchi, 
Effective Amplification of Long Targets From Cloned Inserts and Human Genomic DNA, 91 
PROCEEDINGS OF THE NAT’L ACAD. OF SCIENCES 5695 (1994).  It is possible to PCR 
amplify sequences of DNA up to approximately forty-thousand bases.  Id. at 5698.  
For comparison, the human genome is billions of bases long. 
 22  See, e.g., Bruce A. Roe et al., Protocols for Recombinant DNA Isolation, Cloning, and 
Sequencing, http://www.genome.ou.edu/protocol_book/protocol_index.html (last 
visited Apr. 7, 2012) (explaining that even the simplest cloning procedure involves 
many steps and will take several days to complete). 
 23  Subin Mary Zachariah & Leena K. Pappachen, A Study of Genetic Engineering 
Techniques In Biotechnology Based Pharmaceuticals, 3 INTERNET J. NANOTECHNOLOGY 1 
(2009), available at http://www.ispub.com/journal 
/the-internet-journal-of-nanotechnology/volume-3-number-1/a-study-of-genetic-
engineering-techniques-in-biotechnology-based-pharmaceuticals.html. 
 24  The, supra note 20. 
 25  Id.; INSULIN RECOMBINANT, DRUGBANK.CA, http://www.drugbank.ca/drugs
/DB00030 (last visited Nov. 5, 2011). 
 26  The, supra note 20. 
 27  See generally, Heinemann & Panke, supra note 2. 
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B. Defining the New Technology of Synthetic Biology 
There is no bright line that distinguishes the older rDNA 
technology from the new synthetic biology.28  Scientists began using 
the latter term in light of advanced techniques for chemically 
synthesizing sequences of DNA, along with a growing understanding 
of how multiple genes work in groups to form “gene networks” or 
“gene circuits.”29  Thus, it is not surprising that the term means 
something different depending on one’s technical background.  
Drew Endy, one of the pioneers of synthetic biology, stated that for 
the biologist, the term means “the ability to design and construct 
synthetic biological systems [to] provide[] a direct and compelling 
method for testing our current understanding . . . .”30  For the 
chemist, “synthetic biology is an extension of synthetic chemistry[:] 
the ability to create novel molecules and molecular systems [to allow] 
the development of useful diagnostic assays and drugs, expansion of 
genetically encoded functions, [and] study of the origins of 
life . . . .”31  For the group of people Endy refers to as “re-writers,” the 
term means that “the genomes encoding natural biological systems 
can be ‘re-written,’ producing engineered surrogates that might 
usefully supplant some natural biological systems.”32  And finally, for 
engineers, synthetic biology is an attempt “to combine a broad 
expansion of biotechnology applications with . . . an emphasis on the 
development of foundational technologies that make the design and 
construction of engineered biological systems easier.”33 
For the purposes of this Comment, the technology of synthetic 
biology is summarized as follows: advances in the ability to chemically 
synthesize sequences of DNA, plus a growing understanding of how 
genes function singularly and in groups, allowing scientists to treat 
genes as biological parts that they can use to engineer a living 
organism—much like an engineer would use various parts to build a 
machine.  This Comment adopts this definition because the 
technological capability of designing standardized biological parts is 
necessary for the establishment of open-source synthetic biology.34  
 
 28  See Drew Endy, Foundations for Engineering Biology, 438 NATURE 449, 449 (2005). 
 29  Jeff Hasty, David McMillen & J.J. Collins, Engineered Gene Circuits, 420 NATURE 
224, 224 (2002). 
 30  Endy, supra note 28, at 449.   
 31  Id. 
 32  Id. (internal citation omitted). 
 33  Id. 
 34  See David W. Opderbeck, The Penguin’s Genome, or Coase and Open Source 
Biotechnology, 18 HARV. J.L. & TECH. 167, 168 (2004).  Professor Opderbeck reviews 
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The definition is largely drawn from Endy’s engineering perspective 
of synthetic biology in order to stress the importance of composable 
biological parts that individuals can design and then contribute to a 
synthetic biology commons.  Also, this definition emphasizes that the 
difficulty or ease with which scientists can create biological parts will 
be an important factor in the success or failure of a synthetic biology 
commons.35 
C. Faster, Easier Genetic Engineering via Synthetic Biology 
One of the underlying goals of synthetic biology is to make 
genetic engineering faster and easier.36  This goal can only be 
reached if standardized tools and methods are established that make 
genes and gene networks function predictably and reliably.37  
Unfortunately, current rDNA techniques largely lack any kind of 
standardization, which severely reduces the pace of technological 
innovation.38  Building a car from scratch is analogous.  An 
experienced engineer with established tools and parts can build a car 
from scratch with little difficulty because the function of each part is 
known and standards are in place for parts to work together.  In 
other words, the parts of a car are known to be interoperable because 
there have been “standards” adopted by the community of engineers 
that build them.39  Now, imagine the challenge of building a car from 
 
the aspects of a technology that make it amenable to an “open source” project.  It 
must be possible to break the project into components and each component must be 
manageably small.  With this in mind, I emphasize the development of discrete 
biological parts in my definition of synthetic biology. 
 35  See id.  Professor Opderbeck points out that rDNA technology poses some 
technical problems with respect to component “layers” in the context of open source 
biotechnology.  Id. at 181–82.  For example, manipulating DNA requires specialized 
equipment and expertise.  Advances in synthetic biology, however, might 
significantly lower this open source barrier.  Specifically, advances in DNA synthesis 
methods have the potential to make manipulating DNA sequences easy, fast, cheap, 
and without formal training.  Standardization of biological parts may also fulfill the 
need for a common biotechnology platform.  Professor Opderbeck also notes that to 
establish open source biotechnology, there must exist social-psychological rewards 
and a community of contributors with authoritative voices.  Id. at 186–97.  While 
these two factors are outside the scope of this Comment, the BioBricks Foundation 
could arguably be in the initial stages of fulfilling these needs.  
 36  Reshma P. Shetty, Drew Endy, & Thomas F. Knight, Engineering BioBrick Vectors 
from BioBrick Parts, 2 J. BIOLOGICAL ENGINEERING 1, 1 (2008), available at 
http://www.jbioleng.org/content/2/1/5. 
 37  See Endy, supra note 28. 
 38  See Endy, supra note 28, at 450. 
 39  See Smita B. Brunnermeier & Sheila A. Martin,  Interoperability Cost Analysis of 
the U.S. Automotive Supply Chain, RESEARCH TRIANGLE INSTITUTE (Mar. 1999), available 
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scratch not knowing how each part works or whether individual parts 
can work together.  Without standard parts and tools, the builder 
would work by trial and error, resulting in a significantly longer 
completion time.  This problem is compounded when working with a 
living organism—biological systems are far more complex than a car, 
and every biological part has the opportunity to interact with every 
other biological part.40  Presently, all engineering of novel gene 
networks requires a significant amount of trial and error during 
development.41  For this reason, without standardized biological parts, 
the pace of innovation would be extremely slow. 
To make this point, Endy uses the example of creating a 
biological oscillator.42  An electrical engineer could create several 
working ring oscillators in under an hour.43  In the biological context, 
however, it took two of the world’s best biophysicists a year to make 
an analogous biological oscillator.44  The main difference between the 
two is that electrical engineers have standard parts available to them 
that work predictably and reliably, while molecular biologists do not.45  
If synthetic biological techniques are used to make molecular biology 
more like an engineering discipline, it will rapidly increase the rate at 
which scientists create biotechnology-related products and therapies. 
One field that would benefit from an increase in the pace of 
progress is medicine.  Recently, scientists have taken a synthetic 
biology approach to engineer biological systems as novel therapies in 
a pre-clinical setting.46  For example, scientists engineered a 
bacteriophage (a virus that infects bacterium) that can destroy 
bacterial biofilms resistant to antibiotics.47  Another example is 
bacteria engineered to invade cancer cells in a solid tumor.48  A 
synthetic organism is even being developed to modify the “human 
microbiome,” the endogenous ecosystem of bacteria found in all 
 
at http://www.rti.org/pubs/US_Automotive.pdf. 
 40  See generally Wendell A. Lim, Connie M. Lee, & Chao Tang, Design Principles of 
Regulatory Networks: Searching for the Molecular Algorithms of the Cell, 49 MOLECULAR CELL 
202 (2013). 
 41  See generally Endy, supra note 28. 
 42  Endy, supra note 28 at 449; see generally Warren C. Ruder, Ting Lu, & James J. 
Collins, Synthetic Biology Moving into the Clinic, 333 SCIENCE 1248, 1249 (2011).  
 43  Endy, supra note 28, at 449. 
 44  Id. 
 45  See id., at 450. 
 46  See Ruder, Lu & Collins, supra note 42, at 1251. 
 47  Id. 
 48  Id. 
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healthy people, which is required for normal physiology.49  Scientists 
are engineering the microbiome bacterium to live in the human gut 
with the ability to prevent the secretion of toxins from cholera.50  
Scientists have engineered other bacteria to secrete various factors to 
treat diabetes or HIV.51  Scientists may even be able to engineer a 
laboratory mosquito that is resistant to hosting malaria and that 
would be able to pass the resistance trait into the natural population 
of mosquitoes.52 
All of these advances were the result of manipulating genomes 
by removing and/or adding various parts to alter biological 
pathways.53  These first few attempts at controlling the behavior of an 
organism with synthetic biology techniques—by manipulating a 
relatively modest number of genes—is useful for animal studies.54  But 
in order to be possible in human beings, “it will be necessary to 
identify entirely new modules and components from endogenous 
networks as well as to synthesize and characterize diverse component 
libraries.”55  In order to support human application, scientists will 
require a substantial increase in the degree of control over the 
behavior of synthetic organisms.56  The scientific community has a 
strong motivation to advance the technology of synthetic biology as 
fast as possible given the immense promise in the field of medicine.  
The quicker scientists make advances, the sooner they can develop 
novel therapies to treat human disease. 
III.  ADVANCING GENETIC ENGINEERING THROUGH OPEN-SOURCE 
SYNTHETIC BIOLOGY 
The benefits of synthetic biology’s engineering principles are 
clear: faster, easier, and more novel solutions to the world’s 
biologically addressable problems.  But the question remains: once 
standard biological parts are created, how should they be used in 
order to foster innovation?  Currently, gene patents dominate the 
biotechnology landscape.57  Tens of thousands of human genes are 
patented by various companies who solely own the patent rights to 
 
 49  Id. at 1250. 
 50  Id. 
 51  Id. 
 52  Ruder, Lu, & Collins, supra note 42, at 1294. 
 53  Id. 
 54  Id. 
 55  Id. at 1251. 
 56  See id. 
 57  See Sam Kean, The Human Genome (Patent) Project, 331 SCIENCE 530, 530 (2011). 
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use them.58  Many commentators have posited that these patent rights 
slow the pace of progress in biomedical sciences dramatically.59  
Emerging technologies are, by their very nature, especially vulnerable 
to broad patents that suppress innovation.60  Some commentators fear 
that “foundational patents” (also known as “upstream patents”), 
which are patents that cover an essential aspect of a technology and 
are usually very broad in scope, will stifle the development of 
synthetic biology along with all of its potential benefits.61  This is 
because the technology that a foundational patent covers is 
necessarily incorporated into any downstream research or resulting 
product.62 
One response addressing the potential threat of patents 
inhibiting synthetic biology innovation is to establish a synthetic 
biology commons where standard biological parts are made freely 
available to all.63  Once foundational biological parts are made 
publicly available in such a commons, individual entities would not 
have the right to patent them.64  Furthermore, some commentators 
have argued that this strategy has the added benefit of encouraging 
innovation.65 This “open-source” approach to synthetic biology is 
analogous to the open-source software movement which was wildly 
successful as it resulted in the creation of countless computer 
applications including the Linux operating system.66 
The following subsections examine what it means to be “open-
source” and how those open-source principles are currently applied 
to the emerging technology of synthetic biology.  One organization 
in particular, the BioBricks Foundation, has been established to 
 
 58  Id. at 531. 
 59  See Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The 
Anticommons in Biomedical Research, 280 SCIENCE 698, 698–99 (1998) (arguing that 
patents over various biomedical technologies may result in an “anticommons” where 
intellectual property rights result in underutilization of technology that hinders 
advancement). 
 60  Id. at 698. 
 61  See id.; Sapna Kumar & Arti Rai, Synthetic Biology: The Intellectual Property Puzzle, 
85 TEX. L. REV. 1745, 1757 (2007). 
 62  See Heller & Eisenberg, supra note 59, at 698. 
 63  Joachim Henkel & Stephen M. Maurer, The Economics of Synthetic Biology, 3 
MOLECULAR SYSTEMS BIOLOGY 1, 3–4 (2007), available at http://www.nature.com
/msb/journal/v3/n1/full/msb4100161.html. 
 64  See 35 U.S.C. § 102(a) (2006). 
 65  See Torrance, supra note 10, at 650–51. 
 66  Id. at 654. 
FITZPATRICK (DO NOT DELETE) 10/22/2013  2:26 PM 
1372 SETON HALL LAW REVIEW [Vol. 43:1363 
 
launch an open-source community.67  Subsection III.A will describe 
both what it means to be “open-source” and the terms used to 
maintain openness in the context of computer software.  Subsection 
III.B will discuss the open-source strategy of the BioBricks 
Foundation.  Subsection III.C will consider the problems associated 
with maintaining openness. 
A. Open-Source 
The term “open-source” has become strongly associated with 
computer software code that is made freely available for individual 
use and modification.68  The principles that open-source computer 
programmers established, however, are applicable to other 
technologies, including synthetic biology.  The Open-Source 
Initiative (OSI), which uses the term in the software context, defines 
“open-source” as terms of distribution that comply with specific 
criteria.69  The OSI uses ten different terms of distribution, all of 
which are written with software development in mind.70  But each 
term can be applied to other technologies where non-rivalrous 
information71 is being freely distributed, including the technology of 
synthetic biology.  The most important OSI requirements to ensure 
openness are: allowing free redistribution, allowing derived works, 
and allowing a distribution of licenses.72  The free redistribution term 
requires that a “license shall not restrict any party from selling or 
giving away the software as a component of an aggregate software 
distribution containing programs from several different sources.  The 
license shall not require a royalty or other fee for such sale.”73  The 
derived-works term states that “[t]he license must allow modifications 
and derived works, and must allow them to be distributed under the 
same terms as the license of the original software.”74  Lastly, the 
distribution of license term states that “[t]he rights attached to the 
program must apply to all to whom the program is redistributed 
 
 67  About the BioBricks Foundation, supra note 7. 
 68  Open Source Definition, OPENSOURCE, http://www.opensource.org/osd.html 
(last visited Feb. 11, 2012). 
 69  Id. 
 70  Id. 
 71  See Opderbeck, supra note 34, at 207–08. (“[I]nformation commons theorists 
hold that information is non-rivalrous because an infinite number of people can 
simultaneously think the same idea without diminishing the idea’s content.”).  
 72  Open Source Definition, supra note 68. 
 73  Id.  
 74  Id. 
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without the need for execution of an additional license by those 
parties.”75  Importantly, software developers writing computer code 
have the intellectual property rights—in copyright law—that are 
required to impose these terms on others who would use their 
works.76  The BioBricks Foundation is a pioneering institution that is 
actively seeking to establish an open-source biotechnology 
community by applying open-source principles to the emerging field 
of synthetic biology.77 
B. BioBricks Foundation 
The BioBricks Foundation is an organization established to 
advance the field of synthetic biology by ensuring that the 
fundamental building blocks of synthetic biology are “freely available 
for ethical, open innovation.”78  Toward that end, the BioBricks 
Foundation has established a synthetic biology commons where 
various DNA “parts” are made freely available for public use, applying 
open-source software principles.79 
With the goal of openness in mind, the foundation has created 
User/Contributor contracts—collectively titled “BioBricks Public 
Agreement”—to promote the use and innovation of BioBricks parts.80  
The terms of the BioBricks Public Agreement are meant to 
ameliorate the threat of patent rights over BioBricks parts in an 
attempt to promote their open and free use.81  The main goal of this 
open strategy is to “make biology easier to engineer so as to benefit 
all people and the planet.  Today, it is difficult to share and reuse 
genetically encoded functions due to high transaction costs 
associated with patent-based licensing (i.e., time and money).”82  The 
contracts contain some terms that are analogous to OSI terms of 
distribution.83  The BioBricks Public Agreement is described as “a 
 
 75  Id. 
 76  17 U.S.C. § 101 (2006) (Literary works include words, numbers, or other 
indicia, regardless of the nature of its embodiment). 
 77  See BIOBRICKS, http://biobricks.org (last visited Apr. 2, 2013) (“We believe 
fundamental scientific knowledge belongs to all of us and must be freely available for 
ethical, open innovation.”).  
 78  Id. 
 79  About the BioBricks Foundation, supra note 7. 
 80  The BioBrick Public Agreement, BIOBRICKS, https://biobricks.org/bpa/ (last 
visited Apr. 2, 2013). 
 81  Id. 
 82  Frequently Asked Questions, BIOBRICKS, https://biobricks.org/bpa/faq/ (last 
visited, Apr. 2, 2013). 
 83  Compare The BioBrick Contributor Agreement, BIOBRICKS, 
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scalable contract among parties”—a contract “between one person 
who wants to make a genetically encoded function free to use and 
someone who wants to use it freely.”84  There are two distinct types of 
contract—one for the “Contributor” and one for the “User.”85  The 
Contributor is the person making the biological part available, while 
the User is the person utilizing the part that the contributor 
provided.86  The Contributor contract states that a BioBricks 
Contributor makes “an irrevocable promise not to assert any existing 
or future intellectual property rights over the something against the 
other party to the contract.”87  Furthermore, the Contributor of a 
BioBricks part must disclose the existence of any intellectual property 
rights to the part held either by the Contributor or by a third party.88  
The User contract states that a User promises to “provide attribution 
to the Contributor, where requested, and to respect biological safety 
practices and applicable laws.”89 
Some commentators have noted that the BioBricks Public 
Agreement sets forth more than the mere terms of a license intended 
to prevent disputes over ownership rights.90  Rather, the terms of the 
BioBricks Public Agreement are “an initial effort to draft a legal 
constitution to guide the beneficial development of the field of 
synthetic biology.”91 
C. Challenges Maintaining the BioBricks Commons 
There are several significant challenges to the openness of the 
BioBricks commons.  Importantly, the BioBricks Public Agreement 
does not include some provisions included in the OSI terms of 
distribution.92  Three of these challenges will be discussed specifically 
in this section.  The first challenge is derivation: getting contributors 
to donate derived work back to the BioBricks Foundation and not 
 
http://biobricks.org/wp-content/themes/bbf/bpa-sample.php (last visited Feb. 12, 
2012), with Open Source Definition, supra note 68. 
 84  Frequently Asked Questions, supra note 82. 
 85  Id.  
 86  Id.  
 87  Id. 
 88  The BioBricks Contributor Agreement, supra note 83 (section 4, Intellectual 
Property Rights). 
 89  Frequently Asked Questions, supra note 82; see The BioBricks User Agreement, 
BIOBRICKS, http://biobricks.org/bpa/users/agreement/ (last visited Feb. 12, 2012).  
 90  Torrance, supra note 10, at 663. 
 91  Id. 
 92  See Frequently Asked Questions, supra note 82. 
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assert any intellectual property rights.93  The second challenge is 
motivation: incentivizing individuals or entities that currently hold 
patent rights of biological parts to donate them to the BioBricks 
Foundation in the first place.94  The third challenge is the absence of 
an end product: the open-source synthetic biology community will not 
be able to realize the potential of novel medically relevant inventions 
on its own.95  The first two challenges stem from the terms of the 
BioBricks Public Agreement, while the third challenge is inherent in 
biomedically relevant research.96  Each challenge will be considered 
in turn. 
1. Derivation 
 One of BioBricks Foundation’s open-source community goals is 
to foster the creation of novel biological parts by derivation from the 
parts currently found in the registry.97  Despite this goal, the absence 
of terms in the BioBricks Public Agreement that require all derived 
works to be donated back to the BioBricks Foundation creates a 
challenge.  Unless a User is the inventor of the biological part, she is 
barred from asserting any intellectual property rights over any 
individual biological part once contributed to the BioBricks 
Foundation.98  But there is nothing stopping a user from asserting 
intellectual property rights over a different biological part that is 
derived from BioBricks parts.99  In other words, if a person has signed 
the BioBricks User Agreement and, in using the BioBricks parts, 
creates a new part with a novel function, there is nothing stopping 
that person from patenting that novel part and asserting intellectual 
property rights over it.  In fact, the User Agreement specifically states 
that there is no requirement to give any novel materials or 
applications back to the foundation.100  The BioBricks Foundation 
makes perfectly clear that “[n]ovel materials and applications 
produced using [contributed] parts may be considered for protection 
via conventional property rights.”101  As a result, the BioBricks User 
 
 93  See generally Torrance, supra note 10. 
 94  Id. 
 95  Id. 
 96  Id. 
 97  See About the BioBricks Foundation, supra note 7. 
 98  See 35 U.S.C. § 102 (2006). 
 99  This statement assumes that the derived work is both novel and non-obvious. 
See generally 35 U.S.C. §§ 102, 103 (2006). 
 100  Frequently Asked Questions, supra note 82. 
 101  Id. 
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Agreement is fundamentally different from the traditional open-
source agreement, which requires any derived works to be licensed 
back under the same terms as the original.102  Without a reciprocal 
licensing mechanism in place to ensure that novel biological parts 
will continue to be derived from the past work of users, maintaining a 
cycle of innovation by participants in the synthetic biology commons 
may be challenging. 
2. Motivation 
A second important problem is that there is no clear reason for a 
person with intellectual property rights over a part to surrender those 
rights and donate the part to the BioBricks Foundation.  Arguably, 
the only motivation to forego one’s intellectual property rights is to 
make a philanthropic gesture.103  Professor Andrew Torrance has 
noted that “it is not obvious what incentives contributors would have 
to contribute their BioBricks, especially if they must relinquish any 
intellectual property rights they may have in order to do so.”104 
3. End Product 
There is a third problem that is unique to synthetic biology as 
applied to the field of medicine: there is no immediately usable end 
product.105  Other open-source movements, such as the open-source 
software movement, were wildly successful in part due to the fact that 
a working product resulted from the aggregate work of many 
individuals.106  The quintessential example of open-source success is 
the Linux operating system.107  It can be downloaded and used by 
anyone in the world after thousands of individuals put forth effort 
over many years to make it.108  That is not always the case with 
 
 102  Compare The BioBricks Contributor Agreement, supra note 83, with Open Source 
Definition, supra note 68. 
 103  Torrance, supra note 10, at 660. 
 104  Id. 
 105  See Bernard Munos, Can Open-source R&D Reinvigorate Drug Research?, 5 NATURE 
REVIEWS DRUG DISCOVERY 723, 724 (2006) (“There are, however, significant barriers 
to the deployment of open-source approaches to drug R&D. One is economic. All it 
takes to write open-source software is a laptop and an internet connection. With drug 
research, someone must pay for laboratory expenses and clinical trials.”). 
 106  See, e.g., LINUX, https://www.linux.com/learn/new-user-guides/376-linux-is-
everywhere-an-overview-of-the-linux-operating-system (last visited Sept. 7, 2013). 
 107  See DOWNLOAD LINUX FREE, http://downloadlinuxfree.com/ (last visited Apr. 
6, 2012). 
 108  Id. 
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biotechnology.109  If members of the BioBricks Foundation were to 
engineer a microbe to be a medical therapy, the end product could 
not be immediately used.110 Instead, introduction of the product 
would require lengthy and extremely costly clinical trials as a drug, 
biologic, or medical device.111  It is likely that an entire community of 
BioBricks members would not have the knowledge or resources 
available to undertake this task. 
Thus, there are several problems to overcome in establishing a 
viable open-source synthetic biology movement.  The first is getting 
people and corporations to make their derived works, which may be 
very valuable, available for further public use free of charge.112  The 
second issue is getting people and corporations with intellectual 
property rights to contribute parts.113  The third, in the context of 
designing a medical therapy, is getting a synthetic biology product 
through clinical trials so that it will actually be beneficial.114 
The first two problems have been previously addressed by other 
open-source movements, such as software development and human 
gene haplotype sequencing, which also had to deal with the threat of 
patents stifling progress.115  In the context of those specific 
technologies, several different strategies were devised to maintain 
openness.  Parts IV and V will address three strategies that have been 
applied to other technologies that potentially can be applied to 
maintaining open-source synthetic biology.116  Each of the following 
strategies previously has been evaluated in the context of a specific 
technology and each has been successful in maintaining some degree 
of openness.117  Part IV will introduce these previously proposed 
strategies.  Part V will answer the question of whether any of the 
proposed strategies are applicable to a synthetic biology commons, 
and if so, whether any would be successful.  This Comment will 
evaluate three strategies: Copyright Open-Source approach, the 
HapMap License approach, and the BiOS patent approach. 
 
 109  See Munos, supra note 105. 
 110  Id. 
 111  Id. 
 112  See generally, Torrance, supra note 10. 
 113  Id. 
 114  Id. 
 115  See infra Part IV. 
 116  See infra Part IV & V. 
 117  See infra Part IV. 
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IV. PREVIOUSLY PROPOSED OPEN-SOURCE STRATEGIES 
A. Copyright Open-Source Approach 
Currently, copyright protection for sequences of DNA is not 
available.118  If sequences of DNA could be protected under Copyright 
Law, however, then it would be relatively straightforward to 
implement open-source synthetic biology in an analogous fashion to 
open-source software.119  A license to use the DNA “work” would 
include provisions that require the user to give back to the commons 
any derivative works.120  The General Public License (GPL)121 that has 
been commonly used in open-source software could be easily adapted 
to cover DNA122 and would have the same open-source effect—novel 
sequences of DNA or novel combinations of established sequences 
that have been derived from previous work covered by the GPL would 
remain available to the public. 
Several commentators have suggested that it is feasible for 
sequences of DNA to be covered by copyright law.123  Some observers 
even suggested that this approach could be used to establish open-
source synthetic biology.124  These scholars reasoned that DNA 
sequences are very similar to computer software code because both 
involve a set of software instructions that are first read and then 
executed by hardware.125 Additionally, any unique issues that might 
arise in the context of synthetic biology could be absorbed with a 
relatively small incremental change to copyright law.126 
For example, Dr. Christopher Holman makes the case that 
 
 118  See MICHAEL A. EPSTEIN, MODERN INTELLECTUAL PROPERTY, Ch. 11, II, C 458–59 
(2d ed. 1992) (no cases or statutes have addressed the applicability of Copyright to 
sequences of DNA). 
 119  See Torrance, supra note 10; Christopher M. Holman, Copyright For Engineered 
DNA: An Idea Whose Time Has Come?, 113 W. VA. L. REV. 699 (2011). 
 120  GNU General Public License, Version 3, OPENSOURCE, 
http://www.opensource.org/licenses/gpl-3.0.html (last visited Feb. 11, 2012) (“Each 
time you convey a covered work, the recipient automatically receives a license from 
the original licensors, to run, modify and propagate that work, subject to this 
License.”). 
 121  Id. 
 122  Holman, supra note 119 (arguing that there is a strong similarity between 
computers executing software code and cells expressing genes, which suggests that 
copyright could be easily applied to engineered DNA sequences). 
 123  See id.; Torrance, supra note 10. 
 124  Holman, supra note 119; Torrance, supra note 10. 
 125  Holman, supra note 119, at 712. 
 126  Holman, supra note 119; Torrance, supra note 10. 
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engineered DNA should be protected by copyright law.127  He argues 
that “[t]he major doctrinal leap occurred thirty years ago when 
copyright protection was recognized for computer programs.  In view 
of the close analogy between software and engineered DNA, the 
further extension to encompass engineered genetic sequences is a 
relatively modest incremental expansion.”128  Dr. Holman argues that 
engineered sequences of DNA and computer code both are 
essentially sets of instructions that are read and executed by 
hardware.129  For computer code, the hardware is the group of 
computer components itself; for DNA sequences, the hardware is the 
group of proteins, carbohydrates, and fatty acids that make up a 
living cell.130  Furthermore, advances in biotechnology have allowed a 
high level of creativity in generating DNA sequences.131  This is 
important because the Supreme Court, in Feist Publications, Inc. v. 
Rural Telephone Service Co. Inc.,132 established a minimum threshold for 
a work to be covered by copyright law—the work must contain “a 
modicum of creativity.”133  This is a relatively low threshold that could 
be easily met even with the current state of synthetic biology because 
the technology currently allows for the creation of DNA sequences 
that are different—at least modestly—from what exists in nature.134 
Moreover, in recent years the Supreme Court has consistently 
interpreted the Copyright Clause of the constitution broadly.135  For 
example, in the context of the Copyright Clause, the Supreme Court 
does not interpret the term “writing” literally—photographs, art, 
motion pictures, and sounds have all been considered “writings.”136  
And Congress and the Courts have expanded what constitutes a 
“writing” for the purposes of the Copyright Clause to adapt to 
evolving technology.137  At one point in time, the only expressions 
deemed protectable were those which a human could directly 
 
 127  See Holman, supra note 119. 
 128  Id. at 703. 
 129  Id. 
 130  Id. 
 131  Id. 
 132  Feist Publ’n, Inc. v. Rural Tel. Serv. Co., Inc., 499 U.S. 340 (1991). 
 133  Id. at 346. 
 134  See generally Ruder, Lu & Collins, supra note 42. 
 135  See Holman, supra note 119. 
 136  See Goldstein v. California, 412 U.S. 546 (1973); Kalem Co. v. Harper Bros., 
222 U.S. 55 (1911); Bleistein v. Donaldson Lithographing Co., 188 U.S. 239 (1903); 
Burrow-Giles Lithographic Co. v. Sarony, 111 U.S. 53 (1884). 
 137  Holman, supra note 119, at 710. 
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perceive, such as written words.138  But in 1976 Congress explicitly 
expanded the scope of copyright protection to include expressions 
that could only be read by a machine.139 Through the 1980’s, 
computer software was generally accepted as a type of expression that 
could be protected by copyright, but there was some uncertainty over 
the scope of protection.140  Dr.  Holman sums up the uncertainty: 
[D]id copyright protection extend to object code, which 
could only be read by a computer, or was it limited to 
human readable source code? What about operating system 
software, whose only intended audience is a machine?  Or a 
computer program embodied in computer readable media, 
such as a CD-ROM? Ultimately, all these questions are 
answered in the affirmative.141 
Presently, there is a general consensus in the Courts that 
copyright protection is available for any type of software, regardless of 
its form or the medium in which it is stored.142  And considering the 
expansion of copyright protection in response to changing 
technology, there is good reason to believe that a molecule of DNA 
could be considered merely another type of code analogous to 
computer software and therefore could receive copyright protection. 
Andrew Torrance makes a similar argument, but suggests that 
instead of only thinking about DNA sequences as being analogous to 
computer software, DNA might even be thought of as an actual form 
of computer software.143  This is especially true in the field of synthetic 
biology, where in the future a heightened degree of programmability 
will allow for a potentially limitless amount of creativity.144  This is 
seemingly equivalent to the freedom of a computer programmer to 
create any form of program, constrained only by the computer 
language and hardware itself.  Indeed, Torrance even notes that “one 
of the primary goals of synthetic biology is to engineer cells and 
genes to become ever more like computers and computer 
software.”145  If this approach is adopted, then DNA is already 
 
 138  See White-Smith Music Publ’g Co. v. Apollo Co., 209 U.S. 1 (1908).  
 139  See 17 U.S.C. § 102 (a) (2006). 
 140  Holman, supra note 119, at 710–11. 
 141  Id. 
 142  Id. 
 143  Torrance, supra note 10, at 647 (“Rather than portray DNA sequences as 
analogous to computer software, a synthetic biologist might consider DNA sequences 
actually to be a form of computer software.”). 
 144  See Endy, supra note 28. 
 145  Torrance, supra note 10, at 647.  
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protected by the Copyright Act and no adaptation of law is needed in 
order to protect sequences of DNA. 
B. HapMap Licensing Approach 
Some open-source movements have been relatively successful in 
using a contract-based license to create an information commons in 
the realm of biotechnology.146  One in particular, the International 
HapMap Project, was a joint public-private venture between several 
universities and government agencies from around the world to map 
genetic variation among the world’s human population.147  The stated 
goal of the HapMap Project was to “help researchers find genes 
associated with human disease and response to pharmaceuticals.”148  
The HapMap Project originally created a data access policy that was 
meant to “avoid the filing of intellectual property claims that would 
impede other users’ access to the data.”149  Due to the success of open 
distribution, in 2004—approximately two years after the HapMap 
project had started distributing haplotype data—the HapMap 
Consortium decided that its data access policy was no longer 
required.150  The HapMap Consortium reasoned that enough data on 
human genetic variation was published such that any patent 
applications derived from HapMap data would be considered obvious 
and therefore not patentable.151  Since then, all access to HapMap 
haplotype data is freely accessible to anyone without having to sign a 
license agreement.152 
The data-access policy that the HapMap Consortium formerly 
used included a licensing agreement that a user had to sign before 
gaining access to haplotype data.153  This mandatory licensing 
agreement stated that “you will have to agree to a single condition—
 
 146  See About the International HapMap Project, INT’L HAPMAP PROJECT, 
http://hapmap.ncbi.nlm.nih.gov/abouthapmap.html (last visited Apr. 6, 2012). 
 147  Id. 
 148  THE INTERNATIONAL HAPMAP PROJECT, http://hapmap.ncbi.nlm.nih.gov (last 
visited Feb. 11, 2012).  
 149  Donna M. Gitter, Resolving the Open Source Paradox in Biotechnology: A Proposal for 
a Revised Open Source Policy for Publicly Funded Genomic Databases, 43 HOUS. L. REV. 
1475, 1483 (2007). 
 150  Id. 
 151  See 35 U.S.C. § 103 (2012); Gitter, supra note 149, at 1485; NIH News Release, 
GENOME.GOV, http://www.genome.gov/12514423 (last visited Feb. 12, 2012).  
 152  Data Access Policy for the International HapMap Project, THE INTERNATIONAL 
HAPMAP PROJECT, http://hapmap.ncbi.nlm.nih.gov/cgi-perl/registration (last visited 
Feb. 11, 2012). 
 153  Id. 
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that you will not restrict further use of the individual genotypes, i.e. 
take any action that would in any way restrict the access of others to 
the data produced by the Project.”154  The licensing agreement also 
prohibited distribution of data from the HapMap project to parties 
that had not accepted the terms of the license.155  This provision 
addressed the possibility that a party who signed the license could 
simply give the haplotype data to a third party who had not signed it 
and was not bound by its terms. 
C. The BiOS Patent Approach 
Another past strategy to establish and maintain openness is a 
patent-based approach, which the Biological Innovation for Open 
Society (BiOS) utilized.156  The Center for the Application of 
Molecular Biology to International Agriculture created the BiOS 
initiative in “response to inequities in food security, nutrition, health, 
natural resource management and energy.”157  BiOS currently holds 
the intellectual property rights to several technologies relevant to 
food production.158  For example, BiOS holds patents on several plant 
technologies, including the plant-gene transfer methods, generation 
of plant-gene fusions, and methods for genotyping genetically 
engineered plants.159  Because BiOS holds the patent rights associated 
with those technologies, it can make those technologies freely 
available to anyone who wishes to use them if they agree to the terms 
of the BiOS license.160  The mandatory license requires users to “grant 
back any improvements in the core technology and to make such 
improvements freely available to all others on the same terms that 
BIOS [sic] provided for the original core technology.”161 
 
 154  Id. 
 155  Id. 
 156  BiOS is an initiative of the Center for the Application of Molecular Biology to 
International Agriculture (CAMBIA). See CAMBIA, http://www.cambia.org
/daisy/cambia /home.html (last visited, Feb. 12, 2012). 
 157  BIOS, http://www.bios.net/daisy/bios/home.html (last visited Feb. 11, 2012). 
 158  IP Portfolio Licensable from Cambia, CAMBIA, http://www.cambia.org/daisy
/cambialabs/ip_portfolio.html (last visited Feb. 11, 2012). 
 159  Id. 
 160  Cambia is in the process of abandoning its licensing agreement and material 
transfer agreement requirements in order to maximize the public use of its 
technology.  But the BiOS strategy for maintaining openness is still relevant to the 
discussion because the strategy is still available for any person or entity holding 
patent rights in a technology. See id.  
 161  Robin Feldman, The Open Source Biotechnology Movement: Is it Patent Misuse?, 6 
MINN. J.L. SCI. & TECH. 117, 128 (2004). 
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Some academics, such as Professor Robin Feldman, suggest that 
this grant-back requirement may implicate patent misuse.162  Patent 
misuse occurs when the patent holder attempts to expand the 
physical or temporal scope of a patent monopoly beyond what was 
originally granted in the patent.163  “To the extent that a patent 
holder uses its rights to restrict the disposition of inventions not 
covered by the grant, the patent holder may be engaging in behavior 
that extends the scope of the patent grant and thereby may be subject 
to a claim of misuse.”164  While nothing necessarily precludes 
someone from bringing a claim against BiOS, by Professor Feldman’s 
reasoning it is highly unlikely that BiOS would actually find itself in 
court under a theory of patent misuse because the BiOS grant-back 
requirement is not inconsistent with patent policy and any anti-
competitive effects are outweighed by the pro-competitive benefits.165  
Professor Feldman comes to this conclusion by applying a two-part 
test to the open-source grant-back requirement.166  The first part asks 
whether the grant-back requirements of the patent holder are 
inconsistent with patent policy.167  The second part asks whether the 
grant-back requirement fails the antitrust rule of reason.168  In the 
case of the BiOS initiative, the grant-back requirement is compatible 
with patent policy because it is not intended to create exclusive use of 
any technology; rather, it is intended to promote widespread use and 
foster innovation.169  And the grant-back requirement would not 
violate anti-trust principles because it has the effect of maximizing 
the amount of improved technology that is openly available, rather 
than reduce competition in a technology market.170  Thus, Professor 
Feldman argues that open source biotechnology movements should 
not be considered patent misuse because the grant-back requirement 
does not fail either test. 
V.  APPLICATION OF PAST STRATEGIES TO SYNTHETIC BIOLOGY 
The previous open-source strategies described in Part IV lead to 
the question of whether any of the copyright, license, or patent-based 
 
 162  Id. at 142. 
 163  Id. at 118–19. 
 164  Id. at 141–42. 
 165  Id. 
 166  Id. 
 167  Feldman, supra note 161, at 141–42. 
 168  Id. 
 169  Id. 
 170  Id. 
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approaches to maintaining openness would work in the context of 
synthetic biology.  This section applies these strategies to synthetic 
biology and assesses whether any of them can be used to maintain an 
open-source synthetic biology movement.  Application of these 
strategies to the technology of synthetic biology reveals that none of 
these strategies are ideally suited to maintaining openness.  The 
copyright approach and patent-based approach are especially 
unlikely to be useful because of recent federal circuit decisions and 
prohibitive expense, respectively.  While the license-based approach 
can be applied to synthetic biology, it has several flaws that must be 
overcome in order to sustain an open-source synthetic biology 
movement. 
A. Copyright Availability for Open-Source Synthetic Biology 
The copyright approach to open-source synthetic biology is not 
without problems because the applicability of copyright to sequences 
of DNA is untested.  While various scholars have made several 
compelling arguments that DNA sequences should be covered by 
Copyright Law,171 there is currently no indication that the U.S. 
Copyright Office or Congress would approve the use of Copyright 
Law to protect DNA sequences.172  Also, scholars such as Andrew 
Torrance, Sapna Kumar and Arti Rai have all pointed out that the 
Copyright approach may not work for DNA sequences that already 
exist in nature.173  Indeed, copyright law is intended to prevent 
verbatim copying of a writing, regardless of whether the writing is in 
the form of computer software or DNA sequence.174  And copyright 
law does not extend to “discoveries” and thus, no naturally occurring 
sequences of DNA could be protected under a Copyright.175  While 
designing novel DNA sequences that do not exist in nature may 
become commonplace in the future through synthetic biology, the 
current state of the technology largely involves previously existing 
 
 171  See Holman, supra note 119, at 703; Torrance, supra note 10, at 647. 
 172  See Holman, supra note 119, at 702. 
 173  See generally Torrance, supra note 10; Kumar & Rai, supra note 61 (stating that 
the copyright clause of the constitution was intended to protect the creative works of 
authors, it would not apply to naturally occurring sequences of DNA because those 
sequences would not be creative works having an author). 
 174  17 U.S.C. § 101 (2012) (“Copies are material objects . . . in which a work is 
fixed by any method now known or later developed.”).  
 175  17 U.S.C. § 102 (b) (2012) (“In no case does copyright . . . extend to any . . . 
discovery, regardless of the form in which it is described, explained, illustrated, or 
embodied.”) (emphasis added). 
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genetic code.176  For example, the vast majority of BioBricks parts 
made available in the registry are sequences of DNA taken directly 
from naturally occurring organisms.177 
While the applicability of copyright law to sequences of DNA is 
untested,178 the Supreme Court’s recent views on intellectual property 
rights of DNA suggest copyright protection may, in theory, be 
possible.179  While no court has directly indicated that it would approve 
or disapprove the use of Copyright to protect sequences of DNA, 
there is some indirect indication that it might be receptive to 
copyright protection for novel sequences of DNA.180  The Association 
for Molecular Pathology v. United States Patent and Trademark Office 
(Myriad gene patent case)181 offers some insight into how the U.S. 
courts view intellectual property rights surrounding sequences of 
DNA.  While patents and copyrights are distinct bodies of intellectual 
property law, the Supreme Court’s reasoning in the gene patent cases 
may be an indication of future willingness to allow copyright 
protection for DNA.182 
 In July of 2011, the original Myriad gene patent decision, 
authored by Judge Sweet in the Southern District of New York, held 
that a composition of isolated genomic DNA was not patentable 
 
 176  See, e.g., Promoters/Catalog/Constitutive, PARTSREGISTRY, http://partsregistry.org
/Promoters /Catalog/Constitutive (last visited Feb. 12, 2012) (In this example 
category, all of the BioBricks's constitutively active promoter sequences have been 
cloned from a naturally occurring organism; each sequence has a prokaryotic, 
eukaryotic, or phage origin.). 
 177  Id.  
 178  See MICHAEL A. EPSTEIN, MODERN INTELLECTUAL PROPERTY, Ch. 11, II, C 458–59 
(2d ed. 1992) (no cases or statutes have addressed the applicability of Copyright to 
sequences of DNA). 
 179  See Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F. 
Supp. 2d 181 (S.D.N.Y. 2010), aff’d in part & rev’d in part, 689 F.3d 1303 (Fed. Cir. 
2012), aff’d in part & rev’d in part, 133 S. Ct. 2107 (2013). 
 180  See id. 
 181  Id. 
 182  See Ass’n for Molecular Pathology, 689 F.3d 1303 (Fed. Cir. 2012), aff’d in part & 
rev’d in part, 133 S. Ct. 2107 (2013).  There were two separate issues with respect to 
patent eligibility of DNA sequences.  One issue involved the patentability of cDNA 
sequences, which do not exist in nature and are derived from mRNA.  All three 
judges in the Federal circuit agreed that this particular type of DNA is patent-eligible.  
The other issue involved patentability of isolated genomic DNA.  Isolated genomic 
sequences of DNA do exist in nature; in the context of a whole chromosome.  The 
patentability of isolated genomic DNA was the subject of dispute among the three-
judge panel in the Federal circuit and was ruled patent ineligible by the Supreme 
Court.  See Ass’n of Molecular Pathology, 689 F.3d 1303, aff’d in part & rev’d in part, 133 
S. Ct. 2107 (2013). 
FITZPATRICK (DO NOT DELETE) 10/22/2013  2:26 PM 
1386 SETON HALL LAW REVIEW [Vol. 43:1363 
 
subject matter.183  Judge Sweet seized on the idea that DNA is a carrier 
of information and that this property gives it utility.184  Any isolated 
DNA containing the same sequence information of native DNA is 
therefore a product of nature and unpatentable.185 
On August 16, 2012, a three-Judge panel in the Federal Circuit 
handed down three separate opinions, resulting in a reversal of Judge 
Sweet’s decision.186  Two out of the three judges on the Federal 
Circuit panel completely rejected Judge Sweet’s reasoning, and 
concluded that isolated genomic DNA was patent eligible.187  Judge 
Lourie held that “it is the distinctive nature of DNA molecules as 
isolated compositions of matter that determines their patent 
eligibility” rather than the utility of informational content.188  
Furthermore, Judge Lourie stated that when determining patent 
eligibility of DNA, the “informational content is irrelevant.”189 Judge 
Moore concurred with Judge Lourie on the issue of patent eligibility 
of isolated genomic DNA sequences, but wrote separately to 
emphasize the utility of small isolated fragments of DNA and the tacit 
approval by the United States Patent and Trademark Office and 
congress.190  Judge Bryson’s opinion, however, followed Judge Sweet’s 
original reasoning, concluding that “[t]he nucleotide sequences of 
the claimed molecules are the same as the nucleotide sequences 
found in naturally occurring human genes.”191  Thus, Judge Bryson 
emphasized the information carrying property of DNA rather than its 
physical structure.192 
Most recently, on June 13, 2013, the Supreme Court 
unanimously held that isolated sequences of genomic DNA are not 
patent eligible subject matter.193  Justice Thomas, writing for the 
majority, stated that the patent claims at issue “focus on the genetic 
information encoded in the [DNA].”194  Justice Thomas pointed out 
 
 183  Ass’n for Molecular Pathology, 702 F. Supp. at 227–28. 
 184  Id. at 228–29. 
 185  Id. at 227–29. 
 186  Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 689 F.3d 
1303 (2012).  
 187  See id. at 1303 (2012).  
 188  Id. at 1330. 
 189  Id. 
 190  Id. at 1341–46.  
 191  Id. at 1355. 
 192  Id. 
 193  Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013). 
 194  Id. at 2118. 
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that this emphasis on information is necessary for patent protection 
because otherwise, a would-be infringer could avoid offending any 
patent claims by merely adding a single nucleotide base pair to the 
patented gene, thereby creating a distinctive molecule.195  Thus, in 
order for a patent claim to offer any real protection from 
infringement, the patent claim must be “concerned primarily with 
the information contained in the genetic sequence, not with the 
specific chemical composition of a particular molecule.”196  
Importantly, the Supreme Court also affirmed the District Court’s 
and Federal Circuit’s holding that cDNA sequences, which do not 
exist in nature, are patent eligible.197 
Since the Supreme Court has agreed with Judge Sweet’s 
reasoning and emphasized the information-carrying qualities of DNA, 
a parallel argument could be made that copyright law should be able 
to protect novel DNA sequences.  When the informational aspect of a 
molecule of DNA is emphasized, then one could reasonably argue 
that the genetic information is simply read and executed by other 
cellular machinery in a fashion analogous to a computer reading and 
executing software instructions.198 Thus, if courts emphasize the 
informational aspect of DNA, then some judicial reasoning would 
exist in support of Holman’s and Torrance’s conclusion that 
copyright should be applicable to sequences of DNA much like 
copyright is applicable to computer software.199 
The Court’s willingness to apply copyright law to novel 
sequences of DNA is far from certain.  With the Supreme Court’s 
decision in the Myriad gene patent case, patents are clearly available 
to protect novel sequences of DNA.200  As Kumar and Rai noted, 
“Courts and Congress might be reluctant to layer on an entirely new 
kind of property right, for fear that such rights would hurt rather 
than help innovation.”201  Thus, despite the sound arguments for why 
DNA should be protected under copyright law, it is possible that the 
courts would be reticent to support its use in that context. 
 
 195  Id. 
 196  Id. 
 197  Id. at 2119. 
 198  See Holman, supra note 119 at 712; Torrance, supra note 10 at 647. 
 199  Id. 
 200  See Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 
(2013). 
 201  Kumar & Rai, supra note 61, at 1764. 
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B. Application of HapMap Strategy to the BioBricks Public Agreement 
The application of a HapMap license approach to maintaining 
an open-source synthetic biology movement is possible, but it raises 
issues associated with privity and enforcement.  The HapMap 
licensing terms, which were relatively successful in establishing the 
open use of haplotype data, have some similarities to the current 
BioBricks Public Agreement.202  Both agreements contain terms that 
prohibit placing restrictions on the information, or part, that has 
been made available.203  Importantly, this strategy does not require 
any intellectual property right to bind the signing party to the terms 
of the license.204  Kumar and Rai note that “[t]his contractual 
alternative does not require an underlying property right.  Instead, 
the contract simply imposes conditions as part of the price of 
access.”205  Furthermore, the online nature of a license-based strategy 
requires that the agreed upon web-based contract be enforceable.206  
Professor Donna Gitter has noted that “courts generally enforce 
clickwrap agreements provided the licensee ‘receive[s] notice of the 
license terms before buying or using’ [the software] . . . [and] ‘has 
the ability to return [it] . . . if he does not agree with the 
terms . . . .’”207  Professor Gitter suggests that the HapMap user 
agreement fulfilled these threshold requirements for enforceability.208  
The similar clickwrap nature of the BioBricks agreement suggests 
that it would likely fulfill these threshold requirements as well.  There 
are, however, several issues that still must be overcome. 
1. Third-Party Privity Problems 
Third-parties not in privity of contract who gain access to 
BioBricks parts will create several problems that must be overcome.  
Privity of contract can be described as “that connection or 
relationship which exists between two or more contracting parties. It 
is essential to the maintenance of an action on any contract that 
there should subsist a privity between the plaintiff and defendant in 
respect of the matter sued on.”209  Professor Gitter has noted that a 
 
 202  Compare The BioBricks Contributor Agreement, supra note 83, with Data Access Policy 
for the International HapMap Project, supra note 152.  
 203  Id. 
 204  Id. 
 205  Kumar & Rai, supra note 61, at 1765. 
 206  Gitter, supra note 149, at 1487. 
 207  Id. 
 208  Id. 
 209  RML Corp. v. Lincoln Wood Prods., Inc., 67 Va. Cir. 545, 549 (2005), quoting 
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licensing agreement would not prevent third parties who have gained 
access without having signed the agreement from violating the 
agreement’s terms.210  Gitter points out that the HapMap license 
“does not bind third parties who obtain and use HapMap data 
without downloading it from the HapMap website and who therefore 
are not in privity of contract with the HapMap consortium.”211  A 
similar problem exists in the BioBricks Public Agreement: any third 
party that obtains a BioBrick part without agreeing to the license 
would not be bound by its terms.212  The HapMap Consortium sought 
to overcome this problem by including terms in its licensing 
agreement that specifically prohibited dissemination of HapMap data 
to parties that have not signed an agreement.213  Kumar and Rai 
suggest that this indicates one of the difficulties when using contract 
law to maintain openness: “the comparative weakness of the 
contractual restraints paradoxically requires extremely broad 
restrictions on dissemination.”214  A similar contradiction would exist 
in the context of the synthetic biology commons: the openness of the 
BioBricks parts could only be protected from third parties by severely 
restricting dissemination of the BioBricks parts. 
The BioBricks Foundation has not, however, implemented this 
type of third-party restriction.215  In contrast, the BioBricks 
Foundation’s ethos of openness suggests that it would actually want to 
encourage the free distribution of BioBricks parts to third parties in 
hopes of a third-party eventually making a donation back to the 
foundation.216  Due to the absence of dissemination restrictions, any 
third-party issues that existed at the outset of the HapMap project will 
likely be amplified greatly in the context of the BioBricks 
Foundation. 
2. Enforcement Problems 
In addition to the problems associated with third parties 
violating the terms of a license, there may also be enforcement 
problems with parties who have agreed to the license terms.  For 
 
the definition in Black’s Law Dictionary (4th ed. 1976). 
 210  Gitter, supra note 149, at 1487. 
 211  Id. at 1488–89. 
 212  The BioBricks Contributor Agreement, supra note 83, with Data Access Policy for the 
International HapMap Project, supra note 152. 
 213  Data Access Policy for the International HapMap Project, supra note 152. 
 214  Kumar & Rai, supra note 61, at 1764. 
 215  Frequently Asked Questions, supra note 82. 
 216  Id. 
FITZPATRICK (DO NOT DELETE) 10/22/2013  2:26 PM 
1390 SETON HALL LAW REVIEW [Vol. 43:1363 
 
example, a party may agree to a license that relinquishes any 
intellectual property rights, but that party may later ignore the 
provision and file for a patent anyway.217  There is no reason to 
believe that the patent would be void under this circumstance.218  As 
Professor David Opderbeck noted, “[n]othing in the Patent Act 
would suggest that a patent could be invalidated because some of the 
underlying data was derived from a database in violation of the 
database’s terms of use.  Thus, it is unlikely that the [license] 
provides any meaningful remedy once a patent has been filed.”219  In 
terms of the BioBricks Public Agreement, although an individual 
could fail to disclose the existence of a pending patent on a 
biological part, the individual’s resulting patent would not thereby be 
invalidated due to this violation.220  Thus, users may disregard the 
terms of the BioBricks Public Agreement, which are meant to 
maintain openness, without any real recourse for the BioBricks 
Foundation.221 
There are further issues that arise if the Foundation decided to 
enforce the terms of the BioBricks Agreement in court.  Gitter notes 
that bringing suit against all parties who violate the user agreement 
would “create a significant financial and administrative strain upon 
the nonprofit research group, which must focus its efforts on 
pursuing research as opposed to enforcing its data access policy.”222  
This certainly applies to the BioBricks Foundation, which is also a 
non-profit organization and has limited financial resources.223  
Additionally, the area of biotechnology is very much an international 
enterprise, and there may be no remedy against people who violate 
the terms of the BioBricks Agreement in other countries.224  As Gitter 
states, “[i]f the user happens to be located in a nation that does not 
enforce clickwrap licenses, then that user might not face legal liability 
for violating the . . . license.”225 
 
 217  See Opderbeck, supra note 34, at 199. 
 218  Id. 
 219  Id. 
 220  Id. 
 221  Id. 
 222  Gitter, supra note 149, at 1489. 
 223  About the BioBricks Foundation, supra note 7 (“The BioBricks Foundation (BBF) 
is a 501(c)(3) public-benefit organization founded in 2006.”). 
 224  See Gitter, supra note 149, at 1489. 
 225  Id. at 1491. 
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C. Application of BiOS Approach to BioBricks 
There are several problems with attempting to maintain the 
synthetic biology commons using a patent-based strategy.  First, for 
this strategy to work, BioBricks would have to hold either a few broad 
foundational patents or a patent on each individual part in the 
collection.  Both of these options pose problems. 
Unlike the BiOS Initiative, the BioBricks Foundation does not 
currently hold the patent rights to any broad foundational patents.226  
While a few broad foundational patents might be successfully used to 
maintain a commons, the difficulty with this approach would be to 
“identify an area of inventive territory that was quite broad but 
nonetheless not suggested either by prior broad patents or by 
information already in the public domain.”227  Considering the 
existence of several issued broad foundational patents, it is not likely 
that the BioBricks Foundation would be successful if it were to 
proceed with this approach. 
The alternative is to obtain a very narrow patent on each 
BioBricks part currently in the registry.  This strategy would not only 
require the BioBricks Foundation to patent each part for which it is 
the inventor, it would also require each individual “inventor” who 
donates his or her  
part to the Foundation  to obtain a patent as well.228  This is not 
practically possible.  Obtaining a patent on a sequence of DNA, or 
any other structure or method, could cost tens of thousands of 
dollars each.229  The BioBricks registry currently holds thousands of 
 
 226  Several members of the BioBricks Board of Directors hold patents as 
individuals, but there is no indication that the Foundation itself is assigned any 
patents. See, e.g., Board of Directors, BIOBRICKS, http://biobricks.org/about-
foundation/board-of-directors/ (Tom Knight, one of the founding members of 
BioBricks, holds over thirty patents). 
 227  Kumar & Rai, supra note 61, at 1765. 
 228  Other members of the BioBricks foundation could not claim to be the 
inventor of biological parts donated by individual contributors. See 35 U.S.C. § 102(f) 
(2006); see also Dennis Crouch, With 102(f) Eliminated, Is Inventorship Now Codified in 
35 U.S.C. 101? Maybe, but not Restrictions on Patenting Obvious Variants of Derived 
Information, PATENTLYO (OCT. 04, 2012), http://www.patentlyo.com
/patent /2012/10/with-102f-eliminated-is-inventorship-now-codified-in-35-usc-
101.html.  
 229  The Cost of Obtaining a Patent in the U.S., IPWATCHDOG, 
http://www.ipwatchdog.com/2011/01/28/the-cost-of-obtaining-patent/id=14668/ 
(last visited Feb. 12, 2012) (Even the simplest technologies costs approximately 
$5,000–7,000 in attorney’s fees to obtain a patent, while more complicated 
technologies can cost in excess of $15,000).   
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BioBricks parts.230  Thus, the aggregate cost of maintaining a synthetic 
biology commons by patenting each individual part would easily be in 
the tens of millions of dollars.  This is a prohibitively large amount, 
even for a large for-profit corporation, and simply is not feasible for 
the BioBricks Foundation. 
VI. A STANDARD SETTING ORGANIZATION (SSO) STRATEGY FOR 
ESTABLISHING, MAINTAINING, AND USING THE END PRODUCTS OF THE 
SYNTHETIC BIOLOGY COMMONS 
Part IV of this Comment introduced various past strategies that 
have been used for maintaining openness in different technological 
areas.231  Part V then applied those strategies to the technology of 
synthetic biology, concluding that a copyright or patent-based 
approach is not possible and a license approach is less than ideal.232  
Each of the previous strategies discussed only address the problem of 
securing derived works of synthetic biology for use in the open-source 
community.  The problems of motivating patent holders to donate 
biological parts in the first place and getting biomedical end products 
into the clinic are not addressed by the patent, copyright, or license 
approaches described in Parts IV and V.  The following subsections 
lay out a novel strategy that may be able to tackle problems of 
maintaining openness while, at the same time, incentivizing 
donations and creating opportunities for realizing biomedical 
breakthroughs. This strategy involves establishing a synthetic biology 
Standard Setting Organization (SSO). 
A. Standard Setting Organizations (SSO) 
An SSO, also known as standard setting consortia, can consist of 
“anything from a loose, unincorporated affiliation of companies, to 
an incorporated entity with offices, marketing, technical and 
administrative staff and a multi-million dollar budget.”233  The goal of 
this type of organization is to set standards that are widely adopted 
throughout an industry in order to enable innovation of a business-
 
 230  There is no official count of the available BioBricks parts, but by simply 
browsing the registry, it is clear that there are many thousands of parts. Registry of 
Standard Biological Parts, PARTSREGISTRY, http://partsregistry.org/Main_Page (last 
visited Apr. 6, 2012). 
 231  See supra Part IV. 
 232  See supra Part V. 
 233  Andrew Upgrove, Forming a Successful Consortium, THE ESSENTIAL GUIDE TO 
STANDARDS, http://www.consortiuminfo.org/essentialguide/whatisansso.php (last 
visited Feb. 12, 2012). 
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service or product.234  Standards are found everywhere in our daily life 
and their importance cannot be overstated.  The classic example is an 
electrical plug and socket235—people in the United States can go to 
any store in the country and purchase any tool or device that requires 
power and be confident that they will be able to go home and the 
plug will fit in the wall socket.  Both the plug on the device and the 
electrical socket in the home are guaranteed to work together 
because the manufacturers of the product and the socket have 
adopted a standard.  Furthermore, “[o]rdinary products like printer 
cartridges and tires come in standardized sizes and specifications, 
which fosters choice and competition in the supply of replacement 
parts.”236  Thus, standards have the beneficial effects of promoting 
efficiency of innovation as well as competition in a marketplace.237 
Standards can be broadly classified into three groups: de facto 
standards, private standards, and government standards.238  De facto 
standards arise naturally in a marketplace when users adopt a 
standard to the exclusion of any competition.239  Government 
standards, in contrast, are promoted and enforced by a government 
entity—for example, the U.S. government selected a uniform 
standard for High Definition television in the 1990s.240  Finally, 
private standards are adopted voluntarily by members of an industry, 
usually after the formation of a private SSO.241  With no requirement 
to join a private SSO, “some flourish, while others enjoy only 
middling success, and some fail to gain traction at all.”242 
At the core of an SSO is the establishment of policies to deal 
with intellectual property rights, namely patents.243  To accomplish 
 
 234  Id. 
 235  Multi-Standard Sockets, THE DIGITAL MUSEUM OF PLUGS AND SOCKETS, 
http://fam-oud.nl/~plugsocket/MultiSockets.html (last visited Feb. 12, 2012). 
 236  Edith Ramirez, The Federal Trade Commission Workshop on Intellectual Property 
Rights in Standard Setting, FTC, 
http://www.ftc.gov/speeches/ramirez/110621ssowkshp.pdf  (2011) (last visited 
Sept. 15, 2013). 
 237  Id. 
 238  Mark A. Lemly, Intellectual Property Rights and Standard Setting Organizations, 90 
CAL. L. REV. 1889, 1899–1901 (2002). 
 239  Id. 
 240  James B. Koback, Jr., Standard Setting, IP and Antitrust, PRACTICING LAW 
INSTITUTE PATENTS, COPYRIGHTS, TRADEMARKS, AND LITERARY PROPERTY COURSE 
HANDBOOK SERIES, PLI Order No. 8816 (June 2006). 
 241  Lemly, supra note 238, at 1899–1901. 
 242  Upgrove, supra note 233. 
 243  Id. 
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this, each SSO establishes a set of rules addressing the intellectual 
property rights of members who have joined.244  Two particularly 
important issues covered in the SSO rules are “whether and when 
patent claims must be disclosed” and the reasonable and 
nondiscriminatory (“RAND”) terms by which a member will license 
patent rights to other members.245  The RAND terms of a private SSO 
could possibly be designed to address the problems of maintaining 
open-source synthetic biology. 
B. A Standard Setting Organization Could Address the Problems of 
Maintaining Open-Source Synthetic Biology 
The establishment of a private SSO might address the problem 
of incentivizing the donation of patented biological parts by creating 
a medium through which the part could be used by an open-source 
community while at the same time protecting the intellectual 
property rights of the donor.  An SSO could also address issues 
involved with using a license to get derivative biological parts donated 
back to an open-source community.  Finally, an SSO could foster 
collaboration between an open-source synthetic biology community 
and private entities in order to introduce synthetic biology products 
into the clinic. 
1.  Motivating Donation of Biological Parts 
An SSO could overcome the problem of motivation by 
generating future value of a patented biological part, while at the 
same time protecting the intellectual property rights of the donor.  In 
some situations donation of parts might be made freely because the 
entities holding patent rights over certain technologies would gain 
access to the innovative thinking of an open-source community.246  
For example, IBM has pledged several hundred patents to the open-
source community in order to foster innovation:247 
IBM is committed to promoting innovation for the benefit 
of our customers and for the overall growth and 
advancement of the information technology field. IBM 
takes many actions to promote innovation. Today, we are 
announcing a new innovation initiative. We are pledging 
 
 244  Id. 
 245  Id. 
 246  See, e.g., Statement of Non-assertion of Named Patents Against OSS, IBM 
http://www.ibm.com/ibm/licensing/patents/pledgedpatents.pdf (last visited Feb. 
12, 2012). 
 247  Id. 
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the free use of 500 of our U.S. patents, as well as all 
counterparts of these patents issued in other countries, in 
the development, distribution, and use of open source 
software. We believe that the open source community has 
been at the forefront of innovation and we are taking this 
action to encourage additional innovation for open 
platforms.248 
IBM likely is willing to donate patents because those patents are 
more valuable if used by the masses of an open-source community 
than languishing undeveloped by the company.  Future value can be 
generated from the use of patented technology by a community, and 
companies like IBM can later capitalize on those technological 
advances.  There is no reason to think that this perceived future value 
is limited to use with software.  It is entirely possible that 
biotechnology companies and universities, which hold patents on 
foundational technologies relevant to synthetic biology, would 
similarly value work done by the open-source community of the 
BioBricks Foundation. 
But convincing patent holders to donate the presently valuable 
intellectual property rights to an open-source community will be 
more challenging.  This is despite the fact that an open-source 
community can also generate future value from technology patents 
no matter the present value.249  Patent holders may be hesitant to 
donate their biological parts to the BioBricks Foundation via the 
standard BioBricks Public Agreement because it would prevent 
enforcement of any rights against users.250  The terms of the Public 
Agreement create a risk for an entity that has invested large sums of 
money in obtaining a patent over valuable sequences of DNA because 
a competitor could theoretically sign its own BioBricks Public 
Agreement and then be able to infringe patent rights with impunity.  
By donating a valuable biological part to the BioBricks Foundation, a 
patent holder might inadvertently give up rights to a direct 
competitor. 
This problem could possibly be overcome by a direct agreement 
between the BioBricks Foundation and a patent holder, in which it is 
agreed to allow the use of patented technology by BioBricks 
Foundation members, without actually signing the Contributor 
 
 248  Id. 
 249  See Micheal Fauscette, The Value of Open Source, IDC ANALYST CONNECTION, 
available at http://www.redhat.com/f/pdf/IDC_749_CarveOutCosts.pdf  (last visited 
Apr. 6, 2012). 
 250  See The BioBrick Public Agreement, supra note 80. 
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Agreement.  This potential solution, however, leaves open the 
possibility that the patent holder could decide to assert intellectual 
property rights at a later date, stopping all future innovation with the 
part.  It is unlikely that members of the BioBricks Foundation would 
want to invest time developing a technology only to be forced to stop 
at some future date. 
The establishment of a private SSO would create a medium 
through which the patented biological part could be given to 
BioBricks members while at the same time protecting the intellectual 
property rights of the donor.  The private SSO would include a 
unique provision to achieve this end.  The SSO contract would 
contain an ex ante RAND term that creates a sliding scale based on the 
non-profit or for-profit nature of the entity using the patented 
material.  For the non-profit organization, the reasonable and 
nondiscriminatory license fee would be zero.  For all other 
organizations joining the private-SSO, the license terms would follow 
the fair market value of the patent rights.  Using RAND terms of this 
nature will motivate patent holders of biological parts to donate them 
to an open-source community because future value will be generated 
on the part, and competitors would not have the opportunity to 
exploit a donation. 
2. An SSO Addresses Issues of Enforceability Involved with a 
Licensing Agreement 
As discussed in Section V above,251 one of the problems with 
using a contract licensing approach to maintaining openness in the 
BioBricks Foundation is that a party does not have any real recourse 
if another party violates the terms.252  For example, a donor of a 
biological part could make a promise not to assert any patent rights 
over a donated part, but then later demand that the part not be used.  
To remedy this, donation of biological parts under the umbrella of 
an SSO would make it perfectly clear that the agreement is not simply 
an agreement among parties to use the patented material, but rather 
the adoption of a standard part in which time and money will be 
invested.  This strong declaration that a standard is being adopted 
will bring with it several aspects of protection that exist in common 
law. 
One legal theory that exists in common law is equitable estoppel.  
Equitable estoppel is a legal principle that protects one party from 
 
 251  Supra Part V. 
 252  See supra Part V. 
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another party’s intentional, voluntary conduct.253  The Federal Circuit 
Court of Appeals has articulated a three-part test to determine 
whether a party may use equitable estoppel to bar a patent 
infringement claim.254  First, the patent holder must lead the 
infringer, by misleading conduct, to reasonably infer that no property 
rights will be asserted.255  Types of misleading conduct include 
“specific statements, action, inaction, or silence where there was an 
obligation to speak.”256  Second, the infringer must have relied on the 
misleading conduct of the patent holder.257  Third, the infringer must 
be materially prejudiced by allowing proceedings to continue.258 
There is also case law demonstrating that when a patent holder 
induces another party to adopt a standard in the context of an SSO, 
the patent holder cannot arbitrarily enforce his or her rights at a later 
date.259  An example of this application of estoppel can be found in 
Stambler v. Diebold, Inc.260  In that case, the plaintiff allowed the 
American National Standards Institute (ANSI) to adopt, as an 
industry standard, a technology relating to card validation of ATM 
machines.261  It was well known throughout the industry that the ANSI 
was considering adopting this standard, and it was also known that 
plaintiff held a patent on similar technology.  Furthermore, the 
plaintiff sat on the ANSI committee, which adopted the standard.262  
Before official adoption, plaintiff had concluded that the proposed 
standard infringed his patent, but did not disclose this belief to other 
members of the committee.263  It was not until ten years later, when 
the standard was fully entrenched in ATM machine technology, that 
the plaintiff brought suit for patent infringement.264  Ultimately, 
Judge Platt held that there was evidence of “misleading conduct on 
the part of the plaintiff that may have led the defendant to conclude 
that plaintiff did not intend to enforce his patent,” and further held 
 
 253  See BLACK’S LAW DICTIONARY, 253 (3d ed. 1996). 
 254  A.C. Aukerman Co. v. R.L. Chaides Constr. Co., 960 F.2d 1020 (Fed. Cir. 
1992). 
 255  Id. 
 256  Id. 
 257  Id. 
 258  Id. at 1028. 
 259  Stambler v. Diebold, Inc., 11 U.S.P.Q.2d  (BNA) 1709 (E.D.N.Y. 1988). 
 260  Id. 
 261  Id. at 1713.  
 262  Id. 
 263  Id. 
 264  Id. 
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that the conduct was intentional.265  The court used the theory of 
estoppel to deny the plaintiff the right to enforce the patent, 
reasoning that the plaintiff had a duty to speak out rather than allow 
the industry to adopt the standard.266  Judge Platt found it especially 
telling that the plaintiff had waited “while an entire industry 
implemented the proposed standard and then when the standards 
were adopted assert[ed] that his patent covered what manufacturers 
believed to be an open and available standard.”267 
In light of the Federal Circuit’s three-part test and the holding 
of Stambler v. Diebold, the BioBricks Foundation could clearly be 
afforded the protection of estoppel for a biological part donated 
under a SSO.  If a BioBricks part contributor tried to revoke the 
license of a patent after donating a biological part, all the elements of 
equitable estoppel would be fulfilled.  First, the BioBricks Foundation 
would have reasonably inferred that the contributor did not enforce 
the patent because of the acceptance of the contributor’s donation.  
Second, BioBricks would have relied on that agreement by depositing 
the DNA part into the registry.  Third, the BioBricks Foundation 
would be materially prejudiced by later enforcement because the 
Foundation would have built subsequent biological parts that are 
uniquely composable with the original donated part; i.e. the donated 
part is adopted as a standard.  While all the elements of equitable 
estoppel might be available absent the formal adoption of any 
standards, the strong declaration that a SSO is adopting a standard 
makes fulfillment of the second and third prongs abundantly clear. 
An alternative legal theory for preventing the assertion of patent 
rights over an adopted standard is that of an implied license.268  The 
primary difference between an implied license and equitable 
estoppel is that “that implied license looks for an affirmative grant of 
consent or permission to make, use, or sell.”269  Under this theory, the 
BioBricks Foundation would be protected from enforcement of 
patents that are acquired after a biological standard part has been 
adopted.270  An illustration of this type of protection can be found in 
AMP Incorporated v. United States.  In that case, AMP entered into a 
 
 265  Id. at 1714. 
 266  Id. 
 267  Id. 
 268  AMP Inc. v. United States, 389 F.2d 448 (Ct. Cl. 1968). 
 269  Wang Labs., Inc. v. Mitsubishi Electronics of America, Inc., 103 F.3d 1571, 1581 
(Fed. Cir. 1997) 
 270  See AMP Inc., 389 F.2d at 449. 
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contract with the government to furnish “60 experimental models of 
[a] wire splicing tool.”271  The contract granted the government “an 
irrevocable, non-exclusive, nontransferable and royalty-free” license 
to use the tool.272  After AMP shipped the items, it discovered that its 
patent on the tool had been infringing another company’s patent.273  
AMP purchased the rights to the other company’s patent and then 
tried to revoke the original license it granted the government.274  The 
court held that an implied license existed between AMP and the 
government, even though the government would have been 
infringing the third party’s patent.275  The court reasoned that a 
license cannot be negated if there is no change in the structure of the 
invention.276 
The holding of AMP Incorporated can be applied to biological 
parts adopted as a standard in an SSO setting.  If an SSO member 
were to donate a biological part and subsequently acquire a patent on 
that part, an implied license would prevent the member from being 
able to enforce the after-acquired patent rights against BioBricks or 
any other members of the SSO.  Furthermore, some courts have 
expanded the scope of implied license to include actions that fall 
short of express licenses.277  Thus, in the context of an SSO, when a 
biological part is formally adopted as a standard, it would indicate to 
members of the SSO that there is an implied license to use the part, 
based on the agreed upon terms.278 
3.  Enforcing SSO Terms and Bringing Synthetic Biology to 
the Clinic 
A standard setting organization creates a scenario where 
proprietary entities and open-source communities would have an 
aligned interest in the standard that is adopted.  The patent holder 
benefits from an increased value of an adopted standard; the parties 
using the patented technology would benefit from the enhanced 
ability to innovate and collaborate through use of the standard.  This 
 
 271  Id. 
 272  Id. 
 273  Id. 
 274  Id. 
 275  AMP Inc., 389 F.2d at 448. 
 276  Id. 
 277  See Wang Labs., Inc., 103 F.3d at 1582 . 
 278  See id. (The court looked to the entire course of conduct by the plaintiff, 
including the fact that they encouraged adoption of their technology as a standard, 
when concluding that an implied license defense was available). 
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alignment of interest could significantly benefit the BioBricks 
Foundation because the financial resources of a for-profit 
corporation might be used to prevent any individual member of the 
SSO from “gaming” the system.279  For example, an SSO member that 
promotes the use of a patented technology, but later tries to enforce 
patent rights on unreasonable terms, could be sued under one of the 
legal theories described above.280  Unfortunately, this would require 
financial resources that the BioBicks Foundation does not have on its 
own.  If, however, the interests of the other SSO members were 
aligned with that of the BioBricks Foundation, then a SSO member 
with money to spend could incidentally protect the interest of the 
BioBricks Foundation in trying to protect its own self-interest.  Thus, 
the otherwise impracticable legal recourse of equitable estoppel and 
implied license becomes available to the BioBricks Foundation in the 
context of an SSO. 
Also, the aligned interests of the BioBricks Foundation with the 
for-profit members of the SSO make it possible to address a problem 
regarding the establishment of a synthetic biology commons that no 
other previously proposed strategy could.  Establishment of an SSO 
may help in getting finished, medically relevant products of BioBricks 
members out of the lab and into the clinic.  For-profit biotechnology 
companies have the resources281 and expertise available to undergo 
the arduous clinical trial process.282  Also, clinical trials last many 
years, and the single entity of a corporation could stay focused on 
seeing the process through, without having to rely on any individual 
person to complete the process.283  These are endeavors that a 
synthetic biology commons could not achieve by its very nature, with 
 
 279  See Lemly, supra note 238 at 1899. 
 280  See A.C. Aukerman Co. v. R.L. Chaides Constr. Co., 960 F.2d 1020 (Fed. Cir. 
1992); AMP Inc. v. United States, 389 F.2d 448 (Ct. Cl. 1968). 
 281  Avik Roy, How the FDA Stifles New Cures, Part I: The Rising Cost of Clinical Trials, 
FORBES (Apr. 24, 2012), http://www.forbes.com/sites/aroy/2012/04/24/ 
how-the-fda-stifles-new-cures-part-i-the-rising-cost-of-clinical-trials/ (“[A] recent total 
[of] R&D spending from the 12 leading pharmaceutical companies from 1997 to 
2011. . . found that they had spent $802 billion to gain approval for just 139 drugs: a 
staggering $5.8 billion per drug.”) 
 282  There are a host of regulations that govern the conduct of clinical trials 
involving both human and non-human animal subjects. See FDA Regulations Relating 
to Good Clinical Practice and Clinical Trials, FDA, 
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ 
ucm155713.htm#FDARegulations (last visited Sept. 16, 2013). 
 283  The time it takes to complete a clinical trial ranges from years to decades. See 
Clinical Trials.gov, http://clinicaltrials.gov/show/NCT00249873 (last visited Sept. 16, 
2013).  
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many individuals investing little time and money and producing 
something big with their aggregate work.  Thus, with such an 
alignment of interests, the novel biological parts made by BioBricks 
members could be used freely by all for-profit members of the SSO.  
These novel biological parts could then be used to derive therapies, 
which can be patented, thereby incentivizing investment into clinical 
trials.  To keep the cycle of innovation going, the for-profit patented 
technologies could be adopted as standards and used further by 
BioBricks members under the same SSO terms. 
VII.    CONCLUSION 
The emerging technology of synthetic biology promises to have 
a huge impact on industry and medicine.284  With that in mind, efforts 
should be made to promote the development of the technology in a 
way that maximizes the speed of innovation.  In the world of 
biotechnology, where patents dominate,285 an open-source approach 
to synthetic biology may be a good way to drive the technology 
forward and avoid potential stifling effects of intellectual property 
rights.  This Comment has reviewed some of the problems associated 
with an open-source approach to synthetic biology and the various 
strategies used in the context of other technologies for maintaining 
openness.  This Comment argues that a patent or copyright approach 
for maintaining openness is not possible and that a license approach 
is less than ideal.  Here, a novel SSO approach is proposed that not 
only could maintain openness, but also motivate donation of 
synthetic biological parts and help bring biomedical advances closer 
to clinical trials.  The stated goal of the BioBricks Foundation is to 
“accelerate the pace of innovation, collapse development timelines 
and speed time-to-market of inventive synthetic biology-based 
solutions.”286  Private SSOs have achieved these same ends with 
various other technologies.287  Thus, even though the BioBricks 
Foundation strategy for advancing synthetic biology involves largely 
open-source principles, the establishment of a formal private SSO 
may better advance the Foundation’s goals.  In a world where 
intellectual property rights over foundational technologies threaten 
 
 284  Brent Erickson et al., Synthetic Biology: Regulating Industry Uses of New 
Biotechnologies, 333 SCIENCE 1254 (2011). 
 285  Kean, supra, note 57, at 531 (2011). 
 286  The SBx.0 Series, BIOBRICKS, http://sb5.biobricks.org/files/BioBricksSB5flyer-
v2.pdf (last visited June 4, 2013). 
 287  Upgrove, supra note 233. 
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to stifle progress, creative thinking is necessary in order to advance 
synthetic biology and unlock the vast potential it has to benefit the 
world. 
